Welcome to our dedicated page for Citius Pharmaceuticals SEC filings (Ticker: CTXR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Citius Pharmaceuticals filings document a Nasdaq-listed biopharmaceutical issuer with common stock registered on The Nasdaq Capital Market and a majority-owned oncology subsidiary. Recent Form 8-K disclosures cover material definitive agreements, registered direct offerings, pre-funded warrants, common warrants, unregistered equity securities and amendments to a promissory note involving Citius Oncology.
The company’s regulatory filings also record LYMPHIR commercial updates, international shipment disclosures, investigator-initiated oncology study announcements, and other material events incorporated through press-release exhibits. Proxy materials document annual meeting matters, including director elections, auditor ratification and shareholder voting results.
Citius Pharmaceuticals, Inc. (CTXR) reports that Nasdaq has granted an extension through February 8, 2027 to regain compliance with the $1.00 per share minimum bid price requirement for continued inclusion on the Nasdaq Capital Market under Listing Rule 5550(a)(2), the Bid Price Rule. The company will be deemed back in compliance if its common stock closes at or above $1.00 for at least ten consecutive business days before that deadline, after which Nasdaq would send written confirmation. If Citius does not regain compliance by the deadline, Nasdaq will issue a notice that its common stock is subject to delisting, and Citius may appeal to a Nasdaq hearings panel. CTXR shares continue to trade on the Nasdaq Capital Market, and the company states it is evaluating options to regain compliance but notes there is no assurance it will do so.
Citius Pharmaceuticals, Inc. reported its first meaningful commercial activity for LYMPHIR, generating $7.1 million in net revenue for the nine months ended June 30, 2026, with a gross profit of $5.5 million. Total assets were $142.3 million, including $17.0 million of cash, up from $4.3 million at September 30, 2025, largely due to equity financings, warrant exercises and a new term loan at its majority-owned subsidiary Citius Oncology.
The company recorded a nine-month net loss of $49.4 million and used $23.0 million of cash in operating activities. Management cites a “substantial doubt” going-concern uncertainty, estimating current cash resources fund operations only through November 2026 and highlighting the need for additional capital and successful commercialization of LYMPHIR and future products. Citius Oncology incurred about $20.1 million in termination and related fees after its prior bulk drug substance manufacturer ended their agreement, and both Citius Pharma and Citius Oncology received Nasdaq notices for minimum bid-price noncompliance. A term loan of up to $25.0 million (with $10.0 million funded) provides additional liquidity but carries interest of at least 12.75% and is secured by Citius Oncology’s assets.
Citius Pharmaceuticals, Inc. reported fiscal third quarter 2026 results centered on the launch of LYMPHIR, its targeted immunotherapy commercialized through majority-owned Citius Oncology. Revenue was $1.49 million for the quarter and $7.11 million for the first nine months of fiscal 2026, all from LYMPHIR commercial sales.
Cash and cash equivalents were $17.0 million as of June 30, 2026. The company recorded a quarterly net loss attributable to common stockholders of $8.86 million and a nine‑month net loss of $38.3 million, with a nine‑month operating loss of $52.9 million and net cash used in operating activities of $23.0 million. Inventory totaled $22.6 million.
Management highlighted growing LYMPHIR adoption, including availability at 44 leading oncology centers and nationwide deployment of an expanded 29‑person commercial and medical affairs organization. Early‑stage data in combination with pembrolizumab and as a pre‑CAR‑T therapy showed encouraging response rates, and late‑stage programs Mino‑Lok and Halo‑Lido have completed pivotal and Phase 2b trials, respectively.
CVI Investments, Inc. and Heights Capital Management, Inc. report beneficial ownership of 3,008,529 Citius Pharmaceuticals common shares, representing 9.9% of the class. The position consists entirely of shares issuable upon exercise of warrants, which are subject to 4.99% and 9.99% beneficial ownership limits that restrict exercisability. Heights Capital Management, Inc., as investment manager to CVI Investments, Inc., may exercise shared voting and dispositive power over these shares and may be deemed a beneficial owner, while both reporting persons disclaim beneficial ownership beyond their pecuniary interest. Citius had 27,106,884 shares outstanding (excluding warrant shares) as referenced in a Form S-3 registration statement.
Citius Pharmaceuticals’ majority-owned subsidiary Citius Oncology provided an update on the commercial rollout of LYMPHIR for relapsed or refractory cutaneous T-cell lymphoma. During the quarter ended June 30, 2026, new institutions ordering LYMPHIR increased 78% quarter over quarter, and vials ordered by institutions rose 31%. LYMPHIR is now available in 42 institutions, and the company is targeting formulary inclusion at 100 priority institutions by year-end, with more than 20 additional institutions anticipated during the current quarter. Management estimates the initial CTCL market for LYMPHIR currently exceeds $400 million, supported by near-universal payer coverage and an expanding wholesaler network, with revenue recognized when wholesale orders are placed and filled.
LYMPHIR is an IL2-receptor-directed cytotoxin approved in the U.S. in December 2025 for adults with relapsed or refractory Stage I–III CTCL after at least one prior systemic therapy. The therapy carries a boxed warning for capillary leak syndrome, which occurred in 27% of clinical trial patients, including a 0.8% fatal incidence, and is also associated with infusion-related reactions, hepatotoxicity, visual impairment, and embryo-fetal toxicity, requiring close monitoring and dose modifications based on severity.
Citius Pharmaceuticals, through its subsidiary Citius Oncology, reported early Phase 1 data on LYMPHIR (denileukin diftitox-cxdl) combined with pembrolizumab in recurrent or refractory gynecologic cancers. In 21 efficacy-evaluable patients from a 25-patient study, 48% achieved clinical benefit, with a median progression-free survival of 20.5 months in this subgroup.
The heavily pre-treated population had a median of five prior therapies, and more than half had prior PD-1 or PD-L1 treatment. Investigators described durable responses and manageable tolerability, including activity in relapsed or refractory endometrial cancer. The study was investigator-initiated, open-label, and dose-escalation, and was not designed or powered to prove efficacy.
The company emphasized that LYMPHIR’s use in gynecologic malignancies remains investigational and outside its FDA-approved indication in cutaneous T-cell lymphoma. A Phase 2 expansion study is being planned, while ongoing translational work aims to identify biomarkers and refine future development strategies for this chemo-free immunomodulatory approach.
Citius Pharmaceuticals registers up to 5,431,473 shares of common stock issuable upon exercise of warrants. This preliminary prospectus covers (i) up to 5,076,143 shares issuable upon exercise of Common Warrants and (ii) up to 355,330 shares issuable upon exercise of Placement Agent Warrants, offered for resale by the selling stockholders. The company will not receive proceeds from resales, but could receive up to $4,803,000.81 in the aggregate if all warrants are exercised for cash; such proceeds are allocated to working capital. The prospectus discloses Nasdaq bid-price noncompliance notice and recent financings including a registered direct offering that raised approximately $4.5 million net proceeds.
Citius Pharmaceuticals reported fiscal second quarter 2026 results, highlighted by initial LYMPHIR commercial traction and significantly higher operating losses. Revenue reached $1,667,298 for the quarter and $5,611,409 for the first half, compared with no revenue a year earlier, generating $4,493,323 in gross profit.
Operating expenses rose sharply, driving an operating loss of $32,194,786 and a net loss attributable to common stockholders of $29,451,925 for the first half. The company ended March 31, 2026 with $4,590,174 in cash and cash equivalents and total assets of $132,540,579. Management highlighted LYMPHIR’s launch progress, including strong payer coverage, and recent financings, including a $5 million registered direct offering and up to $36.5 million in Citius Oncology debt and equity commitments.
Citius Pharmaceuticals reported its first meaningful LYMPHIR sales but remains deeply unprofitable and capital constrained. Net revenue reached $5.6M for the six months ended March 31, 2026, generating gross profit of $4.5M. However, total operating expenses of $45.7M, including large general and administrative costs and amortization of in-process R&D, led to a net loss of $37.5M and a loss per share of $1.34.
Cash and cash equivalents were $4.6M with negative working capital of about $23.3M, and operating activities used $14.3M of cash over six months. The company recognized a $3.8M gain from selling New Jersey net operating losses but also recorded about $20.1M of termination-related charges and a $19.7M contract cancellation fee after its LYMPHIR bulk drug substance manufacturer ended the supply agreement and exited microbial production.
Management’s going concern note states there is substantial doubt about Citius’s ability to continue beyond November 2026 without new funding. Subsequent events include a $5.0M registered direct offering at $0.985 per share, approximately $11.5M of Citius Oncology warrant-inducement proceeds, and a loan facility of up to $25.0M for Citius Oncology bearing at least 12.75% interest. Both Citius Pharma and Citius Oncology also received Nasdaq notices for minimum bid-price deficiencies.